Haemonetics Co. (NYSE:HAE – Get Rating) CEO Christopher Simon sold 832 shares of the stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $56.10, for a total transaction of $46,675.20. Following the sale, the chief executive officer now directly owns 191,327 shares in the company, valued at approximately $10,733,444.70. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of NYSE:HAE opened at $59.04 on Thursday. The company has a market capitalization of $3.02 billion, a price-to-earnings ratio of 70.29, a P/E/G ratio of 2.12 and a beta of 0.44. The firm’s 50 day simple moving average is $56.31 and its 200 day simple moving average is $55.46. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.71 and a quick ratio of 1.05. Haemonetics Co. has a fifty-two week low of $43.50 and a fifty-two week high of $75.34.
Haemonetics (NYSE:HAE – Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The medical instruments supplier reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.05. The business had revenue of $265.00 million for the quarter, compared to the consensus estimate of $257.11 million. Haemonetics had a net margin of 4.37% and a return on equity of 18.57%. Haemonetics’s revenue for the quarter was up 17.8% on a year-over-year basis. During the same period last year, the company posted $0.46 EPS. Equities research analysts expect that Haemonetics Co. will post 2.72 earnings per share for the current year.
Several research analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Haemonetics in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Barrington Research raised their target price on shares of Haemonetics from $71.00 to $77.00 in a research note on Wednesday, May 11th. Raymond James reduced their target price on shares of Haemonetics from $70.00 to $66.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 9th. Finally, Needham & Company LLC lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Thursday, January 27th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $70.75.
Haemonetics Company Profile (Get Rating)
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
- Get a free copy of the StockNews.com research report on Haemonetics (HAE)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.